CureVac NV
1CVAC
Company Profile
Business description
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Contact
Friedrich-Miescher-Strasse 15
TubingenBW72076
DEUT: +49 707198830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,088
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,421.70 | 21.90 | 0.26% |
| CAC 40 | 7,682.25 | 55.41 | 0.73% |
| DAX 40 | 23,317.03 | 201.07 | 0.87% |
| Dow JONES (US) | 41,300.06 | 186.09 | 0.45% |
| FTSE 100 | 8,531.97 | 27.36 | -0.32% |
| HKSE | 22,775.92 | 84.04 | 0.37% |
| NASDAQ | 17,845.60 | 107.44 | 0.61% |
| Nikkei 225 | 36,928.63 | 148.97 | 0.41% |
| NZX 50 Index | 12,467.03 | 29.86 | -0.24% |
| S&P 500 | 5,654.66 | 23.38 | 0.42% |
| S&P/ASX 200 | 8,191.70 | 13.40 | 0.16% |
| SSE Composite Index | 3,352.00 | 9.33 | 0.28% |